ERBB2 and neoplasm: An important aspect of our study was the assessment of the population of patients with HER2-ultralow disease (defined as IHC 0 with incomplete and faint staining in ≤ 10% of tumor cells), a population currently being investigated in DESTINY-Breast06 with T-DXd [24].